Weight Loss Injections and Pregnancy: the Evidence and What It Means for You

What regulators and prescribers base the guidance on

The official position on GLP-1 medicines and pregnancy comes from the medicines' licensed product information, MHRA regulatory decisions, and NHS clinical guidance. The NHS's patient information for tirzepatide states clearly that you should not take it during pregnancy, and that if you plan to become pregnant you should talk to your prescriber in advance. The same applies to semaglutide. This is not a general caution added for completeness; it reflects the absence of safety data in human pregnancies and findings from animal reproduction studies that raise concern.

In those preclinical studies, GLP-1 receptor agonists were associated with reduced foetal weight and structural abnormalities at clinically relevant doses. That evidence does not translate directly to human risk, but in the absence of controlled human data the regulatory position is precautionary and will not shift until long-term post-marketing evidence accumulates. NHS England's guidance on weight-management injections explicitly addresses conception planning as part of routine clinical care for anyone starting these medicines.

The practical implication is straightforward: effective contraception should be in place while you are on treatment. If a planned pregnancy is on the horizon, the conversation with your prescriber should happen before you start, not afterwards.

The contraception interaction that often goes unnoticed

One detail that catches people off guard: tirzepatide can slow gastric emptying enough to reduce how reliably an oral contraceptive pill is absorbed. The NHS advises that women taking oral contraceptives should use an additional non-oral method (barrier contraception, for example) for the first four weeks of tirzepatide treatment and for four weeks after each dose increase. This window covers the period when gastric-emptying effects are most pronounced.

Current evidence does not suggest the same degree of pill-absorption reduction for semaglutide, though the advice is to discuss contraception carefully with your prescriber regardless of which medicine you are taking. If you are relying on oral contraception for pregnancy prevention during GLP-1 treatment, the NHS's tirzepatide guidance is worth reading in full. A quick check of your current contraception method, and whether it needs supplementing, takes under a minute and is well worth doing before starting or increasing your dose.

If you are already using non-oral contraception (an IUD, implant, injection or patch) this interaction does not apply in the same way, but the broader guidance to discuss pregnancy planning with your prescriber still stands.

Stopping treatment: timing, weight regain, and planning ahead

A common question from people weighing up GLP-1 weight loss injections is what happens when treatment is paused for pregnancy. There is no simple answer on wash-out timing that applies uniformly, tirzepatide and semaglutide have different half-lives, and prescriber guidance on the interval between stopping treatment and attempting conception should be taken individually. What is established is that most clinical teams advise stopping before actively trying, and that this should be planned rather than reactive.

Some weight regain is likely after stopping, which is worth being realistic about. This is a feature of how these medicines work rather than a sign that the treatment failed; appetite and metabolic signals tend to return towards baseline once the medicine clears. People sometimes also ask whether bone density is affected by weight loss injections, particularly when weighing up the longer-term implications of pausing or stopping treatment around pregnancy. Returning to treatment after pregnancy and breastfeeding is something our prescribers can discuss with you at the appropriate point, once you and your clinical team have confirmed it is safe to do so.

If you are not yet at a stage of considering pregnancy but want to understand the full picture before starting, the cost and service information and a consultation with our clinical team are reasonable starting points.

Who to involve and what to do next

If you are currently on a GLP-1 medicine and have discovered you are pregnant, stop taking it and speak to your GP or midwife as soon as possible. You can also contact the prescriber or clinical team who issued your prescription. Most providers have an aftercare or support line for exactly this situation.

If you are thinking about starting treatment but know pregnancy is a possibility in the near term, that is a conversation your prescriber needs to have before a prescription is issued, and our guide covering whether you can take weight loss injections while pregnant sets out the key considerations in full. At nume, every consultation is reviewed personally by a GPhC-registered Independent Prescriber, and that review includes a structured assessment of your circumstances, including contraception, pregnancy plans, and anything that would affect whether treatment is appropriate now. There are situations involving other health conditions, such as those explored on our MS and weight loss injections page, where the calculus is similarly careful. The right medicine at the right time is the goal, not just the right medicine.

If you have concerns about a side effect or a suspected adverse event, you can also report it via the MHRA Yellow Card scheme, which covers both medicines and any concerns about the supply you received. For anything urgent, your GP or 111 is the right first contact. Our support team is available seven days a week for aftercare questions.